Research analysts at Bank of America assumed coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $38.00 price target on the stock. Bank of America‘s price target points to a potential upside of 27.47% from the stock’s previous close.
Separately, Evercore ISI assumed coverage on Metsera in a research note on Tuesday. They issued an “outperform” rating for the company.
Read Our Latest Research Report on MTSR
Metsera Stock Down 5.8 %
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- What is a Dividend King?
- Confluent: How Data Streaming May Transform AI
- Dividend Capture Strategy: What You Need to Know
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- How to Buy Cheap Stocks Step by Step
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
